Aileron Therapeutics Inc (NASDAQ:ALRN) major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $9.80, for a total transaction of $1,470,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) traded down $0.48 during trading on Monday, hitting $8.52. 20,760 shares of the stock traded hands, compared to its average volume of 25,973. Aileron Therapeutics Inc has a twelve month low of $8.50 and a twelve month high of $15.48.
Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.07). research analysts expect that Aileron Therapeutics Inc will post -1.76 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of ALRN. Neuberger Berman Group LLC acquired a new stake in Aileron Therapeutics during the second quarter worth $279,000. Laurion Capital Management LP acquired a new stake in Aileron Therapeutics during the second quarter worth $335,000. Vanguard Group Inc. acquired a new stake in Aileron Therapeutics during the second quarter worth $111,000. Citadel Advisors LLC acquired a new stake in Aileron Therapeutics during the second quarter worth $141,000. Finally, Tudor Investment Corp ET AL acquired a new stake in Aileron Therapeutics during the second quarter worth $112,000. Hedge funds and other institutional investors own 7.57% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $19.33.
WARNING: “Aileron Therapeutics Inc (ALRN) Major Shareholder Apple Tree Partners Ii Lp Sells 150,000 Shares” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/05/insider-selling-aileron-therapeutics-inc-alrn-major-shareholder-sells-1470000-00-in-stock.html.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.